Analysis of the nuclear receptor transcription conjugate mechanism for the hormone-resistant prostate cancer and development of the new molecular target treatment

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592402
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Nagoya City University
• Principal Investigator: HASHIMOTO yoshihiro 名古屋市立大学, 医学(系)研究科(研究院), 研究員 (40244561)
• Co-Investigator(Kenkyū-buntansha): KAWAI Noriyasu 名古屋市立大学, 大学院医学研究科, 講師 (20254279) ; KOHRI Kenjiro 名古屋市立大学, 大学院医学研究科, 教授 (30122047) ; NAKANISHI Makoto 名古屋市立大学, 大学院医学研究科, 教授 (40217774) ; HAYASHI Yutaro 名古屋市立大学, 大学院医学研究科, 准教授 (40238134) ; TOZAWA Keiichi 名古屋市立大学, 大学院医学研究科, 准教授 (40264733)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: SRC-3 / PI3K/AKT/mTOR / 分子標的治療

Outline of Final Research Achievements

As our analysis result, cyclin D2, E2, M4, T2 and CDC25A for cell cycle regulator and IGF-I, IGF-II, IRS-1, IRS-2, PIK3CA and AKT1 for AKT signal system and BIRC2, BIRC3 and GADD45B for NFkB signal system were recognized as genes controlled by nuclear receptor transcription conjugate factor SRC-3.
As for cyclin E and CDC25A of cell cycle regulator, not only the binding capacity but also the promoter transcription activity was recognized for androgen receptor, SRC-3 and PI3K/AKT/mTOR-related factor, and can expect participation in hormone-resistant mechanism acquisition of the prostate cancer and application to molecules target treatment.

Free Research Field

外科系臨床医学　泌尿器科学